We have more reasons than ever to be optimistic of a new FDA approved treatment for PWS in 2020.
Just last week we learned of successful enrollment for the second ongoing pivotal PWS clinical trial (Soleno’s Destiny PWS study), which comes on the heels of Millendo’s Zephyr study reaching its enrollment goal (although its still recruiting PWS children age 4-7). These milestones represent a huge step towards finding new treatments for PWS. Now that these two trials have completed enrollment, it’s just a matter of time before the study is completed and data analyzed. If the data is positive, a new drug application could be submitted to the FDA in 2020!